Director: 3P Analytical Instrumentation Laboratory, UWCCC
1104 Rennebohm Hall
Dr. Kolesar is the Director of the Analytical Instrumentation Laboratory for Pharmacokinetics, Pharmacodynamcis and Pharmacogenetics (3P) at the University of Wisconsin Comprehensive Cancer Center and an Associate Professor (CHS) at the University of Wisconsin School of Pharmacy. She completed a specialty practice residency in oncology/hematology and 2 year fellowship in molecular oncology pharmacotherapy at the University of Texas Health Science Center in San Antonio. Dr Kolesar joined the UW faculty in 1996.
Dr. Kolesar's research includes the use of biomarkers and pharmacokinetics to predict response and monitor efficacy of drug and gene therapy, population genotyping for cancer susceptibility and the regulation of gene expression of the two electron reductases. She holds two patents for developing novel technologies for evaluating gene expression and point mutations. She is currently a member of the National Cancer Institutes's Adult Central IRB, chairing the adverse events subcommittee and is a member of the Board of Regents of the American College of Clinical Pharmacy. In addition, Dr. Kolesar chairs the Lung Cancer Biology Subcommittee for the Eastern Cooperative Oncology Group as well as serving on the core committess for the Thoracic and Developmental Therapeutics Committees of ECOG.
Dr. Kolesar teaches in the area of oncology and pharmacogenomics and is a co-editor of the textbooks, "Pharmacogenomocs Handbook", " Pharmacotherapy Essentials" and Pharmacogenomics: Applications to Patient Care.
Molecular markers to predict response and monitor efficacy of drug and gene therapy, population genotyping for cancer